Biotech Power Hour: Surge Round the Bend
DENVER, Colo., Aug 27, 2025 (247marketnews.com)- It’s the final stretch of trading, and several small-cap biotechs are lighting up the tape with fresh catalysts.
Allarity (NASDAQ:ALLR) is dominating today’s biotech headlines, surging over 120% intraday after the FDA awarded Fast Track designation to stenoparib, a PARP/WNT inhibitor for platinum-resistant ovarian cancer.
In a bold show of confidence, the company also launched a $5 million share repurchase program, underscoring management’s belief in its undervaluation and preserving its cash runway into 2026.
Earlier this year, trials revealed two patients have now exceeded 14 months on treatment, pointing to durable efficacy. Expect ALLR to stay hot through after-hours if investor rotation into clinical breakout stories continues.
All eyes are on NovaBay (NYSE:NBY) following its recent announcement of a $0.80 special cash dividend per share, signaling strong shareholder returns. The payout will be made on September 29, with a record date of September 15.
As investors price in the due-bill period, watch for late-day activity and momentum into after-hours as yield-focused traders position for the payout.
Azitra (NYSE:AZTR) continues gaining ground on its novel precision dermatology platform. The company recently dosed the first patient in the Phase 1/2 ATR04‑484 trial targeting EGFRi-associated rash, a widespread oncology side effect. With Fast Track designation already secured and traction building, AZTR could shine if any trial progress or data is hinted at post-market.
LIXTE (NASDAQ:LIXT) is emerging as a high-upside oncology micro-cap. Its lead candidate LB‑100, a PP2A inhibitor in collaboration with GSK for ovarian clear-cell carcinoma, is tailored for treatment‑resistant tumors, offering synergy with both chemotherapy and immunotherapy. With distinguishing long‑life patents and precision potential, LIXT stands out among biotech sleepers primed for breakout. A late-day bid could follow any deeper clinical or partnership updates.
Inno Holdings (NASDAQ:INHD)
INHD is stirring as the sustainable building materials sector heats up. Investors are scrutinizing quarterly updates for signs of commercialization or scaling, if Inno hints at supply deals or pilot wins, today could mark its turnaround momentum.
Vir Biotech (NASDAQ:VIR) is under the microscope as emerging infectious threats and immuno-oncology converge. With a dual-focus pipeline spanning chronic hepatitis delta and innovative T-cell engager therapies, any clinical readouts or FDA dialog could ignite the stock. Hedge positions may start building into the close.
Inovio (NASDAQ:INO) is gaining visibility from its DNA-based vaccine and immune therapy platforms. With hope for advancing COVID or cancer-related candidates, look for any late-quarter progress or public-private trial collaboration news to spark a surge.
Rockwell Medical (NASDAQ:RMTI) is drawing eyes amid growing hemodialysis demands. Investors are eyeing whether new hospital or international contracts surface late in the trading day, potentially lighting a bid as the clock runs down.
Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com